Overview

Multiparametric Imaging in Multiple Myeloma

Status:
Completed
Trial end date:
2021-06-30
Target enrollment:
0
Participant gender:
All
Summary
Patients with Multiple Myeloma will undergo single timepoint Positron Emission Tomography imaging with intravenously injected C11 Methionine to detect viable lesions.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Yingbing Wang
Treatments:
Carbon-11 methionine
Criteria
Inclusion Criteria:

- Diagnosis of Multiple Myeloma with symptomatic bone or soft tissue disease

- Eastern Cooperative Oncology Group status 0 to 2

- Life expectance >= 12 weeks

- Ability to understand and willingness to sign informed consent

- Tissue sampling with genotype data planned within 3 months of C11 positron emission
tomography (PET) imaging

Exclusion Criteria:

- Pregnant or breast feeding

- Claustrophobic reactions and unable to lie still on a bed inside the PET scanner for
60 minutes

- Research related radiation exposure exceeding 50 millisieverts